Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Prostaglandins and lipid modification.

G Sobal1, H Sinzinger

  • 1Department of Nuclear Medicine, University of Vienna, Vienna, Austria. Helmut.Sinzinger@akh-wien.ac.at

Current Pharmaceutical Design
|April 3, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Modification of low-density lipoprotein during radiolabeling with 99mTc using three labeling methods.

The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of...·2006
Same author

Modification of low-density lipoprotein by different radioiodination methods.

Nuclear medicine and biology·2004
Same author

Troglitazone-binding to LDL and its glycated modifications: its role in cell-catalysed and Cu-mediated LDL-oxidation.

Life sciences·2003
Same author

Binding of [99mTc]chondroitin sulfate to scavenger receptors on human chondrocytes as compared to binding of oxidized [125I]LDL on human macrophages.

Journal of receptor and signal transduction research·2002
Same author

Methylene blue-enhanced stability of (99mTc)HMPAO and simplified quality control--a comparative investigation.

Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine·2001
Same author

Calcium antagonists as inhibitors of in vitro low density lipoprotein oxidation and glycation.

Biochemical pharmacology·2001
Same journal

Precision Nanotechnology in Oral Oncology: From Biomarker-Guided Targeting to AI-Driven Theranostics.

Current pharmaceutical design·2026
Same journal

Pharmacological Insights into Medicinal Plants and Phytomolecules for the Management of Alopecia with Mechanistic Perspectives and Therapeutic Potential.

Current pharmaceutical design·2026
Same journal

Addressing Challenges, Regulatory Shifts, and the Need for Cost-Effective Alternatives for Complex Topical Formulations.

Current pharmaceutical design·2026
Same journal

The Mechanism of Huaiqihuang in the Treatment of Nephrotic Syndrome: An Integrated Study Based on Network Pharmacology, Molecular Docking, Molecular Dynamics Simulation, and Experimental Validation.

Current pharmaceutical design·2026
Same journal

Resveratrol and the NLRP3 Inflammasome: Unlocking the Anti-inflammatory Potential of a Natural Compound.

Current pharmaceutical design·2026
Same journal

The Use of Hemostatic Agents in Traumatic Bleeding: One Size Does Not Fit All.

Current pharmaceutical design·2026
See all related articles

Prostaglandins and low-density lipoproteins are key in atherogenesis, influencing plaque formation. Further research is needed to fully understand their complex vascular interactions and roles in disease progression.

Area of Science:

  • Cardiovascular Biology
  • Lipid Metabolism
  • Inflammation & Immunology

Background:

  • Prostaglandins (PG) and low-density lipoproteins (LDL) are integral to atherogenesis.
  • Their interaction within the vascular system is crucial for plaque development and progression.
  • The precise mechanisms of these interactions require further elucidation.

Purpose of the Study:

  • To investigate the intricate relationship between prostaglandins and low-density lipoproteins in the context of atherogenesis.
  • To explore how lipoproteins influence PG production and how PGs affect lipoprotein metabolism.
  • To understand the role of modified LDL and isoprostanes in proatherogenic processes.

Main Methods:

  • Analysis of lipoprotein influence on prostaglandin production by arterial cells and platelets.

Related Experiment Videos

  • Assessment of prostaglandin effects on lipoprotein receptor binding and arterial wall entry.
  • Investigation of LDL modification, including the formation and effects of isoprostanes like 8-epi PGF(2alpha).

    • Main Results:

    • Lipoproteins modulate prostaglandin synthesis in vascular cells and platelets.
    • Prostaglandins influence lipoprotein uptake into the arterial wall.
    • LDL modification leads to the formation of proatherogenic isoprostanes, such as 8-epi PGF(2alpha), which promote vasoconstriction and platelet activation.

    Conclusions:

    • The interplay between prostaglandins and lipoproteins is a significant factor in atherogenesis.
    • Modified LDL and associated isoprostanes contribute to plaque progression through various proatherogenic mechanisms.
    • Further research is warranted to assess the impact of eicosanoids on lipoprotein modification.